

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung

Template web posting date: June 2016

Authors

Lynette M. Sholl, MD*

Department of Pathology, Brigham and Women's Hospital, Boston, MA

Philip T. Cagle, MD†

Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX

Neal I. Lindeman, MD†

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Michael Berman, MD

Department of Pathology, Jefferson Hospital, Jefferson Hills, PA

Kirk Jones, MD

Department of Pathology, University of California at San Francisco, San Francisco, CA

Mari Mino-Kenudson, MD

Department of Pathology, Massachusetts General Hospital, Boston, MA

Joel W. Neal, MD, PhD

Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford, CA

Jan A. Nowak, PhD, MD

Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, IL

Kirtee Raparia, MD

Department of Pathology, Northwestern University, Chicago, IL

Natasha Rekhtman, MD, PhD

Memorial Sloan Kettering Cancer Center, New York, NY

For the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists

*Denotes primary author. † Denotes senior authors. All other contributing authors are listed alphabetically.

Acknowledgement

Jennifer Ruhl, MLIS, CTR

Surveillance, Epidemiology and End Results (SEER) Program, National Cancer Institute, Rockville, MD

© 2016 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these templates without its written authorization. The College hereby authorizes use of these templates by physicians and other health care providers in reporting results of biomarker testing on patient specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these templates for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the templates solely for their individual use in reporting results of biomarker testing for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified templates for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified templates into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the template data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the templates in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified templates is prohibited without a written license from the CAP.

The College of American Pathologists offers these templates to assist pathologists in providing clinically useful and relevant information when reporting results of biomarker testing. The College regards the reporting elements in the templates as important elements of the biomarker test report, but the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these templates as educational tools to assist pathologists in the useful reporting of relevant information. It did not issue them for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the templates might be used by hospitals, attorneys, payers, and others. The College cautions that use of the templates other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

CAP Lung Biomarker Template Revision History

Version: LungBiomarkers 1.3.0.1

Summary of Changes

Version 1.3.0.1 errata:

Updated Explanatory Notes (pages 12-13)

Version 1.3.0.0:

RESULTS

Terminology changes (from Indeterminate to Equivocal).
Added data elements for *ALK* Rearrangements identified.

METHODS

Added Sequencing Type.
Added reporting for Anchored multiplex PCR.
Added more options for reporting MET Region.

Biomarker Reporting Template

Template web posting date: June 2016

Completion of the template is the responsibility of the laboratory performing the biomarker testing and/or providing the interpretation. When both testing and interpretation are performed elsewhere (eg, a reference laboratory), synoptic reporting of the results by the laboratory submitting the tissue for testing is also encouraged to ensure that all information is included in the patient's medical record and thus readily available to the treating clinical team.

LUNG

Select a single response unless otherwise indicated.

Note: Use of this template is optional.

+ SPECIMEN ADEQUACY

+ Adequacy of Sample for Testing (Note A)

- + ___ Adequate
 - + Estimated tumor cellularity (area used for testing): _____%
- + ___ Suboptimal (explain): _____

Note: If "Adequate" not selected, please refer to original laboratory report for explanation.

+ SPECIMEN TYPE

- + ___ Untreated diagnostic specimen
- + ___ Relapse specimen (after treatment; specify: _____)#

When data is available, specify treatment type. This is most relevant to targeted inhibitors associated with specific genomic changes conferring treatment resistance (especially erlotinib, gefitinib, and other EGFR tyrosine kinase inhibitors).

+ RESULTS

+ EGFR Mutational Analysis (Note B)

- + ___ No mutation detected
- + ___ Mutation(s) identified (select all that apply)
 - + ___ Exon 18 Gly719[#]
 - + ___ Exon 19 deletion[#]
 - + ___ Exon 20 insertion^{##}
 - + ___ Exon 20 Thr790Met^{###}
 - + ___ Exon 21 Leu858Arg[#]
 - + ___ Other (specify)^{####}: _____
- + ___ Cannot be determined (explain): _____

EGFR activation mutation associated with response to EGFR tyrosine kinase inhibitors.

Exon 20 EGFR activating mutations are generally associated with resistance to EGFR tyrosine kinase inhibitors such as erlotinib, afatinib, and gefitinib, although insertions at or before position 768 can be associated with sensitivity.

The T790M mutation is typically secondary to other EGFR activating mutations and is associated with acquired resistance to tyrosine kinase inhibitor therapy. If seen in untreated/pre-treated patients, may be present in the germline and indicate a hereditary cancer syndrome, in which case genetic counseling is suggested.

There is limited data on response to EGFR tyrosine kinase inhibitors for many of the uncommon EGFR activating mutations.

+ Data elements preceded by this symbol are not required.

+ EGFR by Mutation-Specific Immunohistochemistry

- + EGFR L858R (clone 43B2)
- + ___ Negative[#]
- + ___ Positive^{##}
- + ___ Equivocal^{###} (explain): _____

+ EGFR Exon 19 Deletion (E746_A750del) (clone 6B6)

- + ___ Negative[#]
- + ___ Positive^{##}
- + ___ Equivocal^{###} (explain): _____

[#] A negative result does not exclude the possibility of EGFR mutations, and testing with molecular methods should be performed if a suitable sample is available.

^{##} Diffuse mutation-specific protein expression in tumor cells is highly correlated with EGFR mutation and as such predicts response to EGFR tyrosine kinase inhibitors.

^{###} Tumors with faint cytoplasmic labeling should be designated as equivocal. This result can rarely occur both with and without mutation.

+ ALK Rearrangement by Molecular Methods (Note C)

- + ___ No rearrangement detected[#]
- + ___ Rearrangement identified^{##}
 - + ___ EML4-ALK (specify variant type, if known): _____
 - + ___ KIF5B-ALK
 - + ___ TFG-ALK
 - + ___ KLC1-ALK
 - + ___ Other ALK rearrangement (specify, if known): _____
- + ___ Cannot be determined (explain): _____

+ Polysomy:

- + ___ Present^{###}
- + ___ Absent

[#] Absence of ALK rearrangement in cancer cells suggests that this tumor is unlikely to respond to treatment with a targeted ALK inhibitor, such as crizotinib.

^{##} ALK rearrangement predicts response to therapy with a targeted ALK inhibitor, such as crizotinib or ceritinib. Some evidence suggests the type of FISH pattern (breakapart versus 5' probe deletion) may have implications for treatment response and outcomes.

^{###} Polysomy involving the ALK locus confirms that fluorescence in situ hybridization (FISH) scoring was carried out in tumor cells but does not predict response to therapy with targeted ALK inhibitors.

+ ALK by Immunohistochemistry

- + ___ Negative[#]
- + ___ Positive^{##}
- + ___ Equivocal^{###} (explain): _____

[#] Absence of ALK protein expression in cancer cells suggests that this tumor is unlikely to harbor ALK rearrangement and to respond to treatment with a targeted inhibitor, such as crizotinib and ceritinib.

^{##} ALK protein expression in cancer cells (based on platform criteria) predicts the presence of ALK rearrangement and response to therapy with a targeted inhibitor, such as crizotinib and ceritinib.

^{###} Tumors with faint cytoplasmic labeling should be designated as equivocal. This result can rarely occur both with and without mutation.

+ ROS1 Rearrangement by Molecular Methods (Note C)

- + ___ No rearrangement detected[#]
- + ___ Rearrangement identified^{##}
- + ___ Cannot be determined (explain): _____

- + Polysomy:
 - + ___ Present^{###}
 - + ___ Absent

Absence of ROS1 rearrangement in cancer cells suggests that this tumor is unlikely to respond to treatment with a targeted ROS1 inhibitor, such as crizotinib.

ROS1 rearrangement predicts a high response rate to therapy with a targeted inhibitor, such as crizotinib.

Polysomy involving the ROS1 locus confirms that fluorescence in situ hybridization (FISH) scoring was carried out in tumor cells but does not predict response to therapy with targeted inhibitors.

+ ROS1 by Immunohistochemistry

- + ___ Negative[#]
- + ___ Positive^{##}
- + ___ Equivocal^{###} (explain): _____

Absence of ROS1 protein expression in cancer cells suggests that this tumor is unlikely to harbor ROS1 rearrangement and to respond to treatment with a targeted inhibitor, such as crizotinib.

ROS1 protein expression in cancer cells is highly sensitive for a rearrangement involving ROS1 but is not entirely specific. Therefore, confirmatory molecular methods should be used when ROS1 protein expression is detected.

Tumors with faint cytoplasmic labeling should be designated as equivocal. This result can rarely occur both with and without mutation.

+ RET Rearrangement by Molecular Methods (Note C)

- + ___ No rearrangement detected[#]
- + ___ Rearrangement identified^{##}
- + ___ Cannot be determined (explain): _____

- + Polysomy:
 - + ___ Present^{###}
 - + ___ Absent

Absence of RET rearrangement in cancer cells suggests that this tumor is unlikely to respond to treatment with a targeted RET inhibitor.

RET rearrangement is associated with response to targeted RET inhibitor therapies, such as cabozantinib and vandetinib.

+ KRAS Mutational Analysis

- + ___ No mutation detected
- + ___ Mutation(s) identified[#] (select all that apply)
 - + Codon 12
 - + ___ Gly12Cys (GGT>TGT)
 - + ___ Gly12Asp (GGT>GAT)
 - + ___ Gly12Val (GGT>GTT)
 - + ___ Gly12Ser (GGT>AGT)
 - + ___ Gly12Ala (GGT>GCT)
 - + ___ Gly12Arg (GGT>CGT)
 - + ___ Specific codon 12 mutation not stated
 - + ___ Other codon 12 mutation (specify): _____
 - + Codon 13
 - + ___ Gly13Asp (GGC>GAC)
 - + ___ Gly13Arg (GGC>CGC)
 - + ___ Gly13Cys (GGC>TGC)
 - + ___ Gly13Ala (GGC>GCC)
 - + ___ Gly13Val (GGC>GTC)
 - + ___ Specific codon 13 mutation not stated
 - + ___ Other codon 13 mutation (specify): _____
 - + Codon 61
 - + ___ Gln61Leu (CAA>CTA)
 - + ___ Specific codon 61 mutation not stated

- + ___ Other codon 61 mutation (specify): _____
- + Other
- + ___ Other codon (specify): _____
- + ___ Cannot be determined (explain): _____

[#] No specific tyrosine kinase inhibitors have been approved for lung adenocarcinomas with KRAS mutations. In addition, KRAS mutations are typically mutually exclusive of EGFR, ALK, and other driver molecular alterations.

+ BRAF Mutational Analysis (Note A)

- + ___ No mutations detected
- + ___ BRAF V600E (c.1799T>A) mutation
- + ___ Other BRAF V600 mutation (specify): _____
- + ___ Cannot be determined (explain): _____

+ ERBB2 Mutational Analysis (Note A)

- + ___ No mutations detected
- + ___ ERBB2 774_775insAYVM insertion mutation
- + ___ ERBB2 776_776G>VC insertion mutation
- + ___ Other ERBB2 exon 20 mutation (specify): _____
- + ___ Other ERBB2 mutation (non-exon 20) (specify): _____
- + ___ Cannot be determined (explain): _____

+ MET Mutational Analysis (Note B)

- + ___ No mutation detected[#]
- + ___ MET D963_splice mutation detected[#]
- + ___ MET D1010N mutation detected[#]
- + ___ MET D1010_splice mutation detected[#]
- + ___ Other MET intron 13 mutation (specify)[#]: _____
- + ___ Other MET intron 14 mutation (specify)[#]: _____
- + ___ Other MET exon 14 mutation (specify)[#]: _____
- + ___ MET exon 14 deletion detected^{##}
- + ___ Cannot be determined (explain): _____

[#] MET mutation detection is typically based on DNA-based sequencing methods and may include coding (exon) or non-coding (intron) variants, most commonly located at or near the intron-exon junctions around exon 14.

^{##} RNA-based reverse-transcriptase polymerase chain reaction or RNA sequencing may detect deletion of MET exon 14 without necessarily indicating the mechanism (DNA-based mutation) leading to the deletion.

+ MET Copy Number Analysis

- + ___ No amplification detected
- + ___ Amplification identified (specify copy number and/or ratio to centromere 7): _____ (copies); _____ (ratio)
- + ___ Cannot be determined (explain): _____

+ Other Markers Tested (Note D)

- + Specify marker: _____
- + Specify results: _____

+ METHODS

+ Sequencing Type

- + ___ Targeted panel sequencing (specify): _____
- + ___ Whole exome sequencing (specify): _____
- + ___ Whole genome sequencing (specify): _____

+ EGFR Exons Assessed (select all that apply)

- + 18
- + 19
- + 20
- + 21
- + Other (specify): _____

+ EGFR Mutational Analysis Testing Method(s) (select all that apply)

- + Direct (Sanger) sequencing
- + Pyrosequencing
- + High-resolution melting analysis
- + Polymerase chain reaction (PCR), allele-specific hybridization
- + Real-time PCR
- + Next-generation (high-throughput) sequencing
- + Mutation-specific immunohistochemistry
 - + 43B2 (L858R) clone
 - + 6B6 (E746_A750del) clone
 - + Other (specify): _____
- + Other (specify): _____

Note: Please specify in Comments section if different testing methods were used for different exons.

+ ALK Rearrangement Testing Method(s) (select all that apply)

- + In situ hybridization (fluorescence [FISH] or chromogenic [CISH])
- + Reverse transcriptase polymerase chain reaction (RT-PCR)
 - + Fusions identified (specify): _____
- + Immunohistochemistry
 - + 5A4 clone
 - + D5F3 clone
 - + Ventana ALK (D5F3) immunohistochemistry (IHC) assay
 - + Other (specify): _____
- + Next-generation (high-throughput) sequencing
- + Anchored multiplex PCR
- + Other (specify): _____

+ ROS1 Rearrangement Testing Method(s) (select all that apply)

- + In situ hybridization (fluorescence [FISH] or chromogenic [CISH])
- + Reverse transcriptase polymerase chain reaction (RT-PCR)
 - + Fusions identified (specify): _____
- + Immunohistochemistry
 - + D4D6 clone
- + Next-generation (high-throughput) sequencing
- + Anchored multiplex PCR
- + Other (specify): _____

+ RET Rearrangement Testing Method(s) (select all that apply)

- + In situ hybridization (fluorescence [FISH] or chromogenic [CISH])
- + Reverse transcriptase polymerase chain reaction (RT-PCR)
 - + Fusions identified (specify): _____
- + Next-generation (high-throughput) sequencing
- + Anchored multiplex PCR
- + Other (specify): _____

+ KRAS Codons Assessed (select all that apply)

- + 12
- + 13
- + 61
- + Other (specify): _____

+ KRAS Mutational Analysis Testing Method(s) (select all that apply)

- + Direct (Sanger) sequencing
- + Pyrosequencing
- + High-resolution melting analysis
- + Polymerase chain reaction (PCR), allele-specific hybridization
- + Real-time PCR
- + Next-generation (high-throughput) sequencing
- + Other (specify): _____

Note: Please specify in Comments section if different testing methods were used for different codons.

+ BRAF Exons Assessed (select all that apply)

- + 11
- + 15

+ BRAF Mutational Analysis Testing Method(s) (select all that apply)

- + Direct (Sanger) sequencing
- + Pyrosequencing
- + High-resolution melting analysis
- + Polymerase chain reaction (PCR), allele-specific hybridization
- + Real-time PCR
- + Next-generation (high-throughput) sequencing
- + Other (specify): _____

+ ERBB2 Exons Assessed (select all that apply)

- + 8
- + 16
- + 20

+ ERBB2 Mutational Analysis Testing Method(s) (select all that apply)

- + Direct (Sanger) sequencing
- + Pyrosequencing
- + High-resolution melting analysis
- + Polymerase chain reaction (PCR), allele-specific hybridization
- + Real-time PCR
- + Next-generation (high-throughput) sequencing
- + Other (specify): _____

+ MET Region(s) Assessed (select all that apply)

- + Intron 13
- + Intron 14
- + Exon 14
- + Other (specify): _____

+ MET Mutational Analysis Testing Method(s) (select all that apply)

- + Direct (Sanger) sequencing
- + Next-generation (high-throughput) sequencing
- + Reverse transcriptase-PCR (RT-PCR)
- + Other (specify): _____

+ MET Copy Number Testing Method(s) (select all that apply)

- + In situ hybridization (fluorescence [FISH] or chromogenic [CISH])
- + Next-generation (high-throughput) sequencing
- + Array comparative genome hybridization (aCGH)
- + Other (specify): _____

+ Testing Method(s) for Other Markers (Note E)

+ Specify: _____

+ COMMENT(S)

Note: Fixative type, time to fixation (cold ischemia time), and time of fixation should be reported if applicable in this template or in the original pathology report (Note F).

Gene names should follow recommendations of The Human Genome Organisation (HUGO) Nomenclature Committee (www.genenames.org; accessed May 25, 2016).

All reported gene sequence variations should be identified following the recommendations of the Human Genome Variation Society (<http://varnomen.hgvs.org>; accessed May 25, 2016).

Explanatory Notes

Background

Over half of lung adenocarcinomas contain one of a number of identifiable genetic alterations; some of these can be targeted by a specific therapeutic inhibitor that is either approved by the Food and Drug Administration (FDA) or in clinical trials. The National Comprehensive Cancer Network (NCCN) recommends testing for *EGFR* mutations and *ALK* rearrangements in all patients with recurrent or metastatic lung adenocarcinomas in order to guide therapy.¹ The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) have prepared a joint guideline that provides a detailed description of the patient and specimen requirements and acceptable testing designs and strategies for the detection of these alterations²; the reader is referred to this guideline for details that are beyond the scope of this document.

Briefly, approximately 20% of lung adenocarcinomas contain an *EGFR* activating mutation that predicts response to therapy with EGFR tyrosine kinase inhibitors such as erlotinib.³⁻⁷ Up to 90% of *EGFR* mutations occur in two hot spots within the kinase domain, as small deletions in the LREA motif of exon 19 or as a leucine to arginine substitution at amino acid 858 (exon 21).^{8,9} Molecular testing (sequencing or PCR-based approaches) is recommended for *EGFR* mutation detection whenever possible.² Immunohistochemistry (IHC) with EGFR mutation-specific antibodies has high specificity, but suboptimal sensitivity: 76% for EGFR L858R and 60% or less for EGFR exon 19 deletions.¹⁰ In addition, these antibodies do not detect less common types of sensitizing EGFR mutations. In particular, EGFR exon 19 deletion antibody recognizes primarily a 15-base-pair deletion (E746_A750del), which comprises ~50% of exon 19 deletions, but inconsistently detects other types of exon 19 deletions.¹¹ Because of suboptimal sensitivity, IHC for EGFR mutations may only have a role in situations in which molecular testing is not available or a sample is insufficient or technically unsuitable for testing, such as due to decalcification. If performed, a note should be included that a negative result does not exclude the possibility of *EGFR* mutations, and testing with molecular methods should be performed if a suitable sample becomes available.

The vast majority of patients with *EGFR*-mutated lung adenocarcinoma treated with EGFR tyrosine kinase inhibitors will relapse as a result of resistance to these drugs. The most common resistance mechanism is acquisition of the *EGFR* exon 20 T790M mutation.¹² However, new covalent inhibitors have shown efficacy against relapsed lung adenocarcinomas with *EGFR* T790M mutations in large phase 2 clinical trials^{13,14} but appear less effective in tumors with alternative resistance mechanisms. Therefore, biopsy at the time of relapse may be required to determine the best course of therapy.

Approximately 5% of lung adenocarcinomas have a chromosomal rearrangement involving the *ALK* gene, most commonly in the form of an intrachromosomal inversion leading to the EML4-*ALK* fusion product associated with *ALK* protein overexpression.¹⁵ Patients with this tumor type are responsive to therapy with *ALK* tyrosine kinase inhibitors, such as crizotinib.¹⁶ Fluorescence in situ hybridization (FISH) using break-apart probes is currently considered the “gold standard” for detection of *ALK* rearrangement, which may manifest as separation of the 5' and 3' FISH probes or as deletion of 5' probe. Although both types of alterations are associated with response to *ALK*-targeted therapies, some studies suggest that 5' probe deletion can rarely represent a false positive FISH result.^{17,18} Detection of *ALK* protein overexpression by IHC using the 5A4 or D5F3 clones is highly sensitive and specific for an *ALK* gene rearrangement in lung adenocarcinoma,¹⁹ and the FDA has approved the use of the Ventana *ALK* (D5F3) CDx Assay as a companion diagnostic for crizotinib.²⁰ According to the current guidelines, other carefully-validated, but non-FDA approved, *ALK* immunohistochemistry assays may also be used to screen for *ALK* rearrangement with confirmation by FISH before initiating *ALK*-targeted therapy.²

Patients receiving *ALK*-targeted inhibitors inevitably acquire resistance to these drugs, often in the form of *ALK* kinase domain mutations. The more potent *ALK* inhibitor ceritinib has shown efficacy in these relapsed patients and has been approved for those who developed resistance to, or could not tolerate, crizotinib. The mechanism of resistance does not clearly predict response to this next line therapy; therefore, the role for rebiopsy in patients with *ALK*-rearranged tumors is not clear.²¹

ROS1 rearrangement occurs in 1% to 2% of non-small cell lung carcinomas and predicts response to crizotinib therapy.^{15,22,23} *ROS1* fusion partners include *SLC34A2*, *CD74*, *TPM3*, *GOPC* (*FIG*), *SDC4*, *EZR*, *LRIG3*, *KDEL2*, and *CCDC6*. Several methods, including FISH, IHC, anchored multiplex or reverse-transcriptase PCR, and next-generation sequencing, may be considered for *ROS1* rearrangement detection^{21,23}; no "gold standard" method has been defined. Notably, IHC using the available D4D6 antibody appears to be a robust screening tool, but due to suboptimal specificity, positive results should be confirmed by another technique.^{24,25}

Currently, no targeted tyrosine kinase inhibitor therapies are specifically approved for *KRAS* mutations. However, *KRAS* testing is often performed in lung adenocarcinomas because (1) *KRAS* mutations are typically mutually exclusive with *EGFR* and *ALK* alterations, (2) *KRAS* mutations are the most common oncogenic alteration in lung adenocarcinoma (~20% to 30% of tumors), and (3) *KRAS* mutation testing is typically quicker, easier, and less costly than testing for *EGFR* and *ALK*.²⁶ Therefore, *KRAS* mutation analysis may be used in a molecular testing algorithm to eliminate the need for other more costly and time-intensive testing.

BRAF mutations are detected in about 5% of lung adenocarcinomas; V600E mutations comprise approximately half of these and are therefore found in 2% to 3% of tumors.²⁷ The role of *BRAF* as a targetable oncogene was recently established in phase II clinical trials combining the *BRAF* inhibitor dabrafenib with the MEK inhibitor trametinib, where this drug combination was associated with a 63% overall response rate in patients with *BRAF* V600E-mutated non-small cell lung carcinoma.²⁸

The utility of *BRAF* V600E mutation-specific IHC is not well established in lung adenocarcinoma. The variable sensitivity and specificity of this immunohistochemistry assay relative to mutation analysis reported in other tumor types suggests it may not be appropriate as a clinical tool for *BRAF* V600E detection in lung tumors.²⁹

MET has been recognized as a putative biomarker in lung adenocarcinoma for many years, with amplification implicated as a mechanism of resistance to *EGFR* inhibitors.³⁰ In rare cases, de novo *MET* amplification has been associated with profound responses to therapy with crizotinib. Recently, splicing variants and insertion-deletion mutations leading to *MET* exon 14 deletion have been found in about 3% of lung adenocarcinomas; these events lead to *MET* activation and are associated with response to crizotinib and cabozantinib.^{31,32} *MET* amplification can be seen in tumors with *MET* exon 14 deletion. *MET* protein overexpression appears to correlate with *MET* amplification, although *MET* immunohistochemistry is controversial as a biomarker for *MET*-targeted therapies.³³

Oncogenic *RET* gene rearrangements have been reported in 1% to 2% of lung adenocarcinoma and are more common in never-smokers.^{34,35} Due to the relative rarity of *RET*-rearranged tumors, phase 3 clinical trials with targeted agents for *RET* have not been conducted yet, but preliminary data from phase 2 trials of a multi-targeted inhibitor cabozantinib in *RET*-rearranged lung tumors are promising. *RET* rearrangements are detectable by FISH; however, the most commonly described rearrangement, *KIF5B-RET*, is a product of small intrachromosomal inversion leading to only a subtle split in the FISH probe signals. Thus, the rearrangement could be difficult to detect in practice.³⁶ Alternative detection methods such as anchored multiplex PCR or next generation sequencing may be useful. The role of *RET* IHC in predicting *RET* rearrangements has not been well evaluated.

Lung adenocarcinomas contain a number of other less common alterations that may lead to treatment with targeted inhibitors but have not yet been studied in large controlled trials nor emerged as standard of care. *ERBB2* exon 20 insertion mutations are established as oncogenic alterations in lung adenocarcinoma; patients whose tumors harbor these mutations have shown response to HER-tyrosine kinase inhibitors in phase I studies.³⁷ Alterations in *MAP2K1* (*MEK1*) are rare (<1% of lung adenocarcinoma) but are highly correlated with a smoking history and may predict sensitivity to MEK inhibitors.³⁸ Alterations leading to PI3K pathway activation, including *PIK3CA* or *AKT1* activating mutations or *PTEN* loss of function may serve as biomarkers for enrollment in PI3K- or AKT-inhibitor trials.³⁹ Recently identified fusion events involving *NRG1* and *NTRK1* (*TRKA*) appear to be rare but distinctive oncogenic events in a subset of lung adenocarcinomas.^{40,41}

Monoclonal antibodies targeting the programmed death-1 receptor (PD-1) (nivolumab [Opdivo] and pembrolizumab [Keytruda]) and its ligand, PD-L1 (atezolizumab [Tecentriq]), are FDA-approved for use in non-small cell lung carcinoma.⁴²⁻⁴⁷ All three drugs have been approved for use in the second line (after progression on conventional first line therapies) for both lung adenocarcinoma and squamous cell carcinoma, and

pembrolizumab has also been approved for use in first line therapy for these indications. Within the clinical trials, PD-L1 expression levels by immunohistochemistry tended to correlate with improved responses to both PD-1 and PD-L1 inhibitors, however the detection antibodies used and scoring cutoffs for the tumor cells and immune cells were highly variable for each drug. Only pembrolizumab has been approved together with a companion diagnostic immunohistochemistry assay (PD-L1 IHC 22C3 pharmDx test); patient tumors are required to show PD-L1 expression in at least 50% of tumor cells in the first line setting and at least 1% of tumor cells in the second line. In contrast, nivolumab and atezolizumab were approved with "complementary" diagnostics PD-L1 IHC 28-8 PharmDx and VENTANA PD-L1 (SP142) assays, respectively.^{48,49,50} Additional immunotherapeutic and combination therapies are expected to receive FDA approval for use in lung cancer in the future, possibly with distinct paired diagnostics. At this point in time, only pembrolizumab therapy requires knowledge of tumor PD-L1 status. National Comprehensive Cancer Network guidelines currently recommend standard PD-L1 IHC testing in all advanced (stage IIIB and IV) lung squamous cell carcinomas and adenocarcinomas for selection of front line pembrolizumab therapy.⁵¹ At the same time, knowledge of EGFR mutation and ALK rearrangement status is also required, because alterations in these genes predict inferior response to immunotherapies.

A. Suboptimal Specimen Definition

Suboptimal specimens may be defined as those with:

- Improper fixation (see fixation guidelines below).
- Low tumor content, as defined by the molecular diagnostics laboratory. The cutoff for acceptable tumor content depends on the method used by the laboratory. Samples with tumor content below the recommended cutoff may be falsely negative and should be reported as indeterminate if no mutations are detected.

B. Other Mutations

Other mutations include uncommon variants including exon 19 insertions or other missense variants in the kinase domain of *EGFR* (exons 18-21) that are not listed above. Silent mutations that are known, common, single nucleotide polymorphisms in the general population do not need to be included here.

C. Polysomy

Polysomy (multiple copies) at the *ALK*, *RET*, and *ROS1* loci may be seen in lung adenocarcinoma and when present confirms that FISH has been performed in a tumor cell population. Current evidence suggests that it does not, however, predict response/resistance to targeted therapies.

D. Other Markers Tested

"Other Markers Tested" should be used to report results from molecular assays not included here that may be relevant to lung cancer therapy. These assays may include, but are not limited to, detection of mutations in genes such as *BRAF*, *ERBB2*, and *PIK3CA*; rearrangements involving *ROS1* and *RET* genes; and *MET* copy number changes (see "Background" section above).

E. Testing Method for Other Markers

This section should be completed if the "Other Markers Tested" section is filled out and should describe the type of analyses performed for alterations in genes other than *EGFR*, *ALK*, and *KRAS*, as detailed in note D.

F. Fixation

Improper fixation can lead to failure to obtain results with PCR/sequencing-based assays or FISH. Common problems include the following:

- Procedures or fixation involving acid (eg, decalcification, Bouin's) may degrade DNA.
- Fixation with heavy metals (eg, Zenker's, B5, B+, zinc formalin) inhibit the enzymes used in PCR.
- Underfixation or overfixation. Fixation for at least 8 hours and less than 72 hours in buffered formalin is recommended; prolonged fixation, particularly in unbuffered formalin, degrades DNA.

References

1. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. *J Natl Compr Canc Netw*. 2011;9(Suppl 5):S1-32; quiz S33.
2. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists,

- International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Mol Diagn.* 2013;15(4):415-453.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med.* 2010;362(25):2380-2388.
 4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 2010;11(2):121-128.
 5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med.* 2009;361(10):947-957.
 6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004;101(36):13306-13311.
 7. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012;13(3):239-246.
 8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004;304(5676):1497-1500.
 9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350(21):2129-2139.
 10. Chen Z, Liu HB, Yu CH, Wang Y, Wang L, Song Y. Diagnostic value of mutation-specific antibodies for immunohistochemical detection of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. *PLoS One.* 2014;9(9):e105940.
 11. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. *J Mol Diagn.* 2010;12(2):169-176.
 12. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005;2(3):e73.
 13. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med.* 2015;372(18):1689-1699.
 14. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. *N Engl J Med.* 2015;372(18):1700-1709.
 15. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med.* 2012;18(3):378-381.
 16. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med.* 2013;368(25):2385-2394.
 17. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res.* 2013;19(15):4273-4281.
 18. Gao X, Sholl LM, Nishino M, Heng J, Janne PA, Oxnard GR. Clinical implications of variant ALK FISH rearrangement patterns. *J Thorac Oncol.* 2015;10(11):1648-1652.
 19. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. *J Thorac Oncol.* 2014;9(9):1255-1263.
 20. US Food and Drug Administration. Medical Devices, Recently-Approved Devices. VENTANA ALK (D5F3) CDx assay - P140025. <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm454476.htm>. Updated July 10, 2015. Accessed December 14, 2015.
 21. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014;370(13):1189-1197.
 22. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol.* 2012;30(8):863-870.
 23. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014;371(21):1963-1971.
 24. Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. *Am J Surg Pathol.* 2013;37(9):1441-1449.

25. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. *Lung Cancer*. 2014;83(2):168-173.
26. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med*. 2005;2(1):e17.
27. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. *Clin Cancer Res*. 2013;19(16):4532-4540.
28. Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *J Clin Oncol*. 2016 Jun 3. [Epub ahead of print]
29. Lasota J, Kowalik A, Wasag B, et al. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the immunohistochemical approach. *Am J Surg Pathol*. 2014;38(9):1235-1241.
30. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*. 2007;316(5827):1039-1043.
31. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discov*. 2015;5(8):850-859.
32. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. *Cancer Discov*. 2015;5(8):842-849.
33. Koeppen H, Yu W, Zha J, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. *Clin Cancer Res*. 2014;20(17):4488-4498.
34. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol*. 2012;30(35):4352-4359.
35. Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. *Br J Cancer*. 2014;110(6):1571-1578.
36. Mizukami T, Shiraishi K, Shimada Y, et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. *J Thorac Oncol*. 2014;9(5):622-630.
37. Gandhi L, Bahleda R, Tolaney SM, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. *J Clin Oncol*. 2014;32(2):68-75.
38. Arcila ME, Drilon A, Sylvester BE, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. *Clin Cancer Res*. 2015;21(8):1935-1943.
39. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014;311(19):1998-2006.
40. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. *Cancer Discov*. 2014;4(4):415-422.
41. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nat Med*. 2013;19(11):1469-1472.
42. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373(2):1627-1639.
43. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373(17):123-135.
44. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. *J Clin Oncol*. 2015;33(18):2004-2012.
45. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018-2028.
46. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823-1833.
47. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 2016;387(10030):1837-1846.

48. US Food and Drug Administration. News & Events. FDA approves Keytruda for advanced non-small cell lung cancer. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm>. Published October 2, 2015. Accessed December 14, 2015.
49. US Food and Drug Administration. News & Events. FDA expands approved use of Opdivo in advanced lung cancer. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm>. Published October 9, 2015. Accessed December 14, 2015.
50. US Food and Drug Administration. Approved Drugs. Atezolizumab (TECENTRIQ). <https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525780.htm>. Published October 19, 2016. Accessed September 1, 2017.
51. NCCN Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. http://www.nccn.org/professionals/physicians_gls/pdf/nscl.pdf. Published July 14, 2017. Accessed September 1, 2017.